Experienced in Secondary Parkinsonism

Dr. Fernando L. Pagan

Mgmc LLC
Washington, DC
Experienced
in Secondary Parkinsonism
Specialties:Neurology
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Fernando Pagan is a Neurologist in Washington, Washington, D.c.. Dr. Pagan and is rated as an Experienced provider by MediFind in the treatment of Secondary Parkinsonism. His top areas of expertise are Parkinson's Disease, Benign Essential Blepharospasm, Lewy Body Dementia (LBD), Orthostatic Hypotension, and Deep Brain Stimulation.

His clinical research consists of co-authoring 54 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in DC
Hospital Affiliations
Medstar Georgetown University Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

MGMC LLC
3800 Reservoir Rd Nw, Washington, DC 20007
202-444-3700

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period
A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period
Enrollment Status: Terminated
Publish Date: March 19, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
Enrollment Status: Withdrawn
Publish Date: March 01, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy
RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy
Enrollment Status: Completed
Publish Date: August 23, 2023
Intervention Type: Drug
Study Drug: Droxidopa
Study Phase: Phase 4
Parkinson's Foundation Quality Improvement Initiative
Parkinson's Foundation Quality Improvement Initiative
Enrollment Status: Completed
Publish Date: July 14, 2023
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies (DLB)
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Drug
Study Drug: Bosutinib Oral Tablet
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Enrollment Status: Unknown
Publish Date: March 14, 2019
Intervention Type: Drug
Study Drug: Nilotinib
Study Phase: Phase 2
View 8 Less Clinical Trials

55 Total Publications

Comparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies.
Comparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies.
Journal: Clinical neuropharmacology
Published: January 13, 2025
Similar Doctors
Expertise in
11
conditions
Dr. Boyd A. Dwyer
Neurology
Expertise in
11
conditions
Dr. Boyd A. Dwyer
Neurology

Amber Hill Physical Therapy Inc

187 Thomas Johnson Dr, Suite 6, 
Frederick, MD 
 (40.7 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Boyd Dwyer is a Neurologist in Frederick, Maryland. Dr. Dwyer and is rated as an Advanced provider by MediFind in the treatment of Secondary Parkinsonism. His top areas of expertise are Secondary Parkinsonism, Migraine, Peripheral Neuropathy, and Autosomal Dominant Partial Epilepsy with Auditory Features. Dr. Dwyer is currently accepting new patients.

Expertise in
42
conditions
Dr. Joseph M. Savitt
Neurology
Expertise in
42
conditions
Dr. Joseph M. Savitt
Neurology

Agape Physical Therapy And Sports Rehabilitation Lp

12 Newport Dr, Suite A, 
Forest Hill, MD 
 (59.2 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph Savitt is a Neurologist in Forest Hill, Maryland. Dr. Savitt and is rated as a Distinguished provider by MediFind in the treatment of Secondary Parkinsonism. His top areas of expertise are Parkinson's Disease, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Progressive Supranuclear Palsy. Dr. Savitt is currently accepting new patients.

Expertise in
3
conditions
Dr. Howard D. Weiss
Neurology
Expertise in
3
conditions
Dr. Howard D. Weiss
Neurology
2411 W Belvedere Ave, Ste 202, 
Baltimore, MD 
 (37.7 mi)
410-367-7600
Languages Spoken:
English

Howard Weiss is a Neurologist in Baltimore, Maryland. Dr. Weiss and is rated as an Advanced provider by MediFind in the treatment of Secondary Parkinsonism. His top areas of expertise are Parkinson's Disease, Lewy Body Dementia (LBD), Secondary Parkinsonism, and Cerebellar Degeneration.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile